Xanthine oxidase and C Reactive Protein: New markers in smokers
Abstract
INTRODUCTION: Smoking causes harmful effects on the human health. Cigarette smoking involved in raising inflammatory markers in plasma like C - reactive protein and also xanthine oxidase.C – Reactive protein which is an inflammatory marker is the indication of pre cardiovascular events. It is also related with the increased risk of stroke, unstable angina and sudden coronary death.
OBJECTIVE: The objective of present study was to find out the serum xanthine oxidaseand C- reactive proteins in smokers and non smokers.
METHODOLOGY: This was a Cross sectional analytical study conducted at three different districts of interior sindh during 2012 to 2013.A total of one hundred thirty one (131) healthy males were included in this study, of these 68 (age20-30 years) were smokers and 63(same age) were non-smokers. All were apparently healthy individuals one hundred thirty one (131) serum samples from age and gender matched smokers and non-smokers were analyzed for the levels of xanthine oxidase by kit methods and C- Reactive proteins by standard kit methods using Nyocard kit.
RESULTS: Smokers in comparison to non-smokers had significantly raised mean serum xanthine oxidase (0.38±0.05 Vs 0.28±0.027mg/dl; p value <0.005) and C reactive proteins (14.62 ± 0.16 mg/LVs 4.81 ± 0.16 mg/L; p value <0.001) levels.
CONCLUSION: The result clearly shows that xanthine oxidase and C-Reactive protein both has significant variations in smokers and may considered as a new marker for the detection of smoking in young adult of age 20 – 30 years.
KEY WORDS: Xanthine oxidase, C- Reactive proteins, Smoking
References
Shah AA, Khand F, Khand TU. Effect of smoking on serum xanthine oxidase, malondialdehyde, ascorbic acid and alpha tocopherol levels in healthy male subject. Pak J Med Sci 2015; 31(1): 146-9.
U.S Department of Health and Human Services. The Health consequences of smoking- 50 years of progress: A report of the Surgeon General Atlanta, GA: U.S. Department of Health and Human Services, Centers for disease control and prevention, National center for chronic disease prevention and health promotion, Office on smoking and health, 2014.
Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
Lao XQ, Jiang CQ, Zhang WS, Adab P, Lam TH, Cheng KK, et al. Smoking, smoking cessation and inflammatory markers in older Chinese men- The Guangzhou Biobank Cohort Study Atherosclerosis 2009; 203: 304-10.
Ata MA, Khand F, Shaikh SS, Ata MA. Effect of smoking on serum xanthine oxidase and malondialdehyde levels in patients with acute myocardial infarction. J Pak Med Assoc 2015 Jan; 65(1):39-42.
Schumacher JN, Green CR, Best FW, Newell MP. Smoke composition: an extensive investigation of the water soluble portion of cigarette smoke. J Agric Food Chem 1997; 25: 310-20.
Teo KK, Ounpuu S, Hawken S, Pandey MR, Valentin V, Hunt D, et al. Tobacco use and risk of myocardial infarction in 52 countries in the Inter heart study: a case-control study. Lancet 2006; 368: 647-58.
Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. J Circulation Am Heart Assoc 2003; 107: 416-21.
Gorman SL, Zweier JL. Evaluation of the role of xanthine oxidase in myocardial reperfusion injury. J BiolChem 1990; 265: 6656-63.
Bhakuni P, Chandra M, Misra MK. Oxidative stress parameters in erythrocytes of post reperfused patients with myocardial infarction. J EnzIhibi Med Chem 2005; 20: 377-81.
Tillet WS, Francis TJ. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930; 52: 561-85.
Shrive AK, Cheetham GM, Holden D, Myles DA, Turnell WG, volanakis JE, et al. J Nat StructBiol 1996; 3: 346-54.
Kushner I. Jiang SL, Zhang D, Lozanski G, Samols D.Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1? Ann N Y AcadSci 1995; 762: 102-7.
Jialal I, Devaraj S, Venugopal SK. Hypertension. 2004; 44: 6-11.
Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obesity 2001; 25: 1327-31.
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
Torres JL, Ridker PM. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Curr OpinCardiol 2003; 18: 471-8.
Sesso HD, Buring JE, Rifai N. C reactive protein and risk of developing hypertension. JAMA 2003; 290: 2945-51.
Fatehuddinkh, Shaikh SS, Ata MA. Evaluation of the effect of smoking on complete blood counts, serum C-reactive proteins and magnesium levels in healthy adult male smokers. JPMA 2015 Jan; 65(1): 59-61.
Das I. Raised C-reactive protein levels in serum from smokers. ClinChimActa 1985; 153(1): 9-13.
Guerrero-Romero F, Rodriguez-Moran M. Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. IntJ ObesRelatMetabDisord 2002; 26: 469-74.
Mendenhall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relationship to cardiovascular risk factors (a population-based cross sectional study). BMJ 1996; 312: 1061-5.
Tracy RP, Macy EM, Bovill EG. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. ArteriosclerThrombVascBiol 1997; 17: 2167-76.
